Retrospective correlation of 68 ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.

Autor: Onal C; Faculty of Medicine, Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, 01120, Adana, Turkey. hcemonal@hotmail.com., Torun N; Faculty of Medicine, Department of Nuclear Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, Adana, Turkey., Oymak E; Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey., Guler OC; Faculty of Medicine, Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, 01120, Adana, Turkey., Reyhan M; Faculty of Medicine, Department of Nuclear Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, Adana, Turkey., Yapar AF; Faculty of Medicine, Department of Nuclear Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University, Adana, Turkey.
Jazyk: angličtina
Zdroj: Annals of nuclear medicine [Ann Nucl Med] 2020 Jun; Vol. 34 (6), pp. 388-396. Date of Electronic Publication: 2020 Mar 27.
DOI: 10.1007/s12149-020-01462-x
Abstrakt: Objective: The aim of the study is to investigate the correlation between the intensity of prostate-specific membrane antigen (PSMA) uptake in primary tumor and clinico-pathological characteristics of non-metastatic prostate cancer patients treated with definitive radiotherapy (RT).
Methods: Using the clinical data of 201 prostate cancer patients who were referred for 68  Ga-PSMA-positron emission tomography (PET/CT) for staging and RT planning, we analyzed the correlations among intermediate- or high-risk disease based on Gleason score (GS), prostate-specific antigen (PSA) level, D'Amico risk group classification, and maximum standardized uptake (SUV max ) of primary tumor.
Results: Primary tumor was visualized via 68  Ga-PSMA-PET/CT scan in 192 patients (95.5%). The median SUV max of primary tumor and metastatic lymph node were 13.2 (range 3.3-83.7) and 11.4 (range 3.6-64.5), respectively. A significant moderate correlation was observed between PSA level and median tumor SUV max as measured by 68  Ga-PSMA-PET/CT (Spearman = 0.425; p < 0.001). Patients with serum PSA > 10 ng/mL, GS > 7, D'Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher tracer uptake in primary tumor than their counterparts. The median SUV max of primary tumor was highest in patients with GS 9. The primary tumor detection rates of 68  Ga-PSMA-PET/CT were 83%, 92%, and 99% for patients with serum PSA ≤ 5.0 ng/mL (14 patients, 7%), PSA 5.1-10.0 ng/mL (45 patients, 22%), and PSA > 10 ng/mL (142 patients, 71%), respectively.
Conclusions: We demonstrated a correlation between prostate tumor characteristics and PSMA tracer uptake. Patients with serum PSA > 10 ng/mL, GS > 7, D'Amico high-risk group classification, and pelvic lymph node metastasis had significantly higher SUV than their counterparts. In addition, the primary tumor detection rate was higher in patients with serum PSA > 10 ng/mL and GS > 7.
Databáze: MEDLINE
Externí odkaz: